Year: 2010
Type: article
Abstract: OBJECTIVE: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. METHODS: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Abeta(1-42)) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). RESULTS: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE epsilon4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. CONCLUSIONS: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.
Source: Neurology
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Foundation for the National Institutes of Health, Alzheimer's Association, Richard and Susan Smith Family Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Novartis, Mayo Foundation for Medical Education and Research, Synarc, Elan, Eisai, National Institutes of Health, Genentech, National Institute on Aging, National Heart, Lung, and Blood Institute, National Institute of Neurological Disorders and Stroke, National Center for Research Resources
Awards: G104586243, G1624380267, G2287182814, G2301694166, G2476215740, G2801376415, A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease, G3146424788, NIA Core Center to Build Neurodegenerative Disease Research Faculty At Penn, National Alzheimer's Coordinating Center, Alzheimers Disease Patient Registry, Parkinson's Disease and Dementia, G4230629791, Alzheimer's Disease Core Center, Molecular substrates of aging and neuron death, G4491021986, Frontotemporal Dementias: Genotypes and Phenotypes, Alzheimer's Disease Cooperative Study (ADCS), Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers, Resource for MRI of Neurodegenerative Disorders, G553888402, G5610321346, Alzheimer's Disease Neuroimaging Initiative, Alzhelmer's Disease Drug Development Program, G6206414941, VITAMIN E TRIAL IN PERSONS WITH DOWN SYNDROME, High Field Neuroimaging of Epilepsy, Frontotemporal degeneration: a basis for clinical trials, EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM, Prediction of cognitive decline with structural, diffusion, and perfusion MRI, The ARIC and Neurocognitive Longitudinal Study, G7805897153, Alzheimer's Disease Cooperative Study, G8390535266, The Aging Brain: Vasculature, Ischemia, and Behavior, G9000038603, Frontotemporal Dementia: Genes, Images, and Emotions, New Approaches to Dementia Heterogeneity, Mayo Alzheimer's Disease Research Center
OpenAlex ID: W2112691652